Healthtech Investors & VC Firms in United States
2067 firms in this list, with a median first check of $500K. 520 of them lead rounds. Generated from verified public data and updated continuously.
Oriza Seed Capital (Oriza Yuandian)
SuzhouPre-Seed–Series A$213K – $60M
9 people
Mitsubishi UFJ Capital
TokyoPre-Seed–Late Stage$952K – $269M
5 people
Fresenius Medical Care Ventures
Bad HomburgSeed–Late Stage
7 people
Storytime Capital
TorontoPre-Seed–Series A
5 people
Bluesky Equities Ltd.
CalgaryPre-Seed–Series A
10 people
Archetype Ventures
TokyoPre-Seed–Growth$875K – $92M
6 people
Ming capital
ShenzhenSeed–Late Stage
6 people
TVM Capital
MunichSeed–Late Stage$1.1M – $16.2M
6 people
Innova Capital Sp. z o.o.
WarsawSeries A–Late Stage$27M – $44M
5 people
Unfold Ventures
WrocławPre-Seed–Late Stage$110K – $1.1M
7 people
Intelligence Ventures
Pre-Seed–Seed$50K
6 people
Zühlke Ventures
ZurichPre-Seed–Series A$165K – $275K
2 people
PreAngel Fund
BeijingPre-Seed–Series A$20K – $1M
4 people
Brand Capital
ChennaiSeed–Growth
9 people
Future Positive Capital
Pre-Seed–Series A
2 people
Partners Investment Co. Ltd.
SeoulSeries A–Late Stage
10 people
Vertex Ventures HC
SingaporeSeed–Growth$500K – $10M
4 people
Auxano
GurugramPre-Seed–Late Stage
6 people
Transcend Capital Partners
Hong KongPre-Seed–Series B$2.5M – $5M
6 people
AddVentures by SCG
BangkokSeed–Late Stage$1.5M – $66M
6 people
Whiz Partners Inc.
TokyoSeed–Late Stage$500K – $5M
6 people
GiTV, Inc.
TokyoSeed–Series A
4 people
NEOM
RiyadhPre-Seed–Series C
15 people
LYZZ Capital
ShanghaiSeed–Series A
5 people
Related lists
Investors & VC Firms in North America (13845)Investors & VC Firms in United States (12980)Investors & VC Firms in Europe (5528)Crypto & Web3 Investors & VC Firms (4819)Investors & VC Firms in Global (4182)SaaS Investors & VC Firms (3878)AI & Machine Learning Investors & VC Firms (3817)Fintech Investors & VC Firms (3737)Investors & VC Firms in Asia-Pacific (3575)Healthtech Investors & VC Firms (3445)
Data sourced from public filings and firms' own websites — see our methodology.


















































































